Alzheimer’s Disease Researchers at California based Leucadia Therapeutics released a panel of eight apps today to help people track memory and cognition. The new apps are ProCogny Memory Tracker, Infinite Mahjong, Iconic Sudoku, Word Recall, Connectors, Image Recall, Pattern Busters, and Speed Demon. The ProCogny Memory Tracker includes a non-clinical version of the proprietary Leucadia Memory Test. There are many digital trackers available to count steps and other measures of physical activity, but few apps track memory and cognitive function. The apps include games and puzzles that exercise different facets of memory such as word recall, reasoning, alternating tasks, matching, object recognition, pattern recognition, and spatiotemporal memory. The apps are available on Apple’s App Store and Google Play in 22 languages.
Age-associated memory decline is more pronounced in people who develop cognitive impairment and Alzheimer’s disease. Neuroscientists believe that maintaining good memory recall is influenced by diet, exercise, and mental stimulation. Scientists at Leucadia Therapeutics used Deep Learning to develop a sophisticated diagnostic algorithm to assess a person’s likelihood of developing Alzheimer’s. This non-invasive method uses CT scans, Leucadia’s Memory Test, and other measures to help predict risk of developing Alzheimer’s years before cognitive impairment develops.
Leucadia’s team developed this game-based platform to assess memory and cognition of participants in their Project Cribrose clinical study. The study participants liked the Leucadia Memory Test so much that the team combined the test with in-house AI and their ProCogny Memory Tracker to make it available to the public. Users can take screenshots of their results and share them. Daily Brain Boosts are rotating collections of mini-puzzles tailored to focus on areas that users had problems with in the Leucadia Memory Test.
Download The Apps
ProCogny Memory Tracker, Infinite Mahjong, Iconic Sudoku, Word Recall, Connectors, Image Recall, Pattern Busters, and Speed Demon for mobile phones and tablets are available on Apple’s App Store and Google Play.
- The apps are available in 22 languages, including Arabic, Chinese (Simplified), Czech, Danish, Dutch, English, Finnish, French, Greek, Italian, Japanese, Korean, Norwegian, Polish, Portuguese, Russian, Spanish, Swedish, Thai, Turkish, Ukrainian, and Vietnamese.
- The basic apps are free but customization and access to premium assets require a monthly subscription of $3.99
- Leucadia is offering a week of full access to new users. Use Promo Code MEMORY2021 for a week of free full access on Apple’s App Store on Google Play
- Click here to download the Apps
Project Cribrose Clinical Study
Leucadia Therapeutics is conducting a 2,000 person clinical study called Project Cribrose. Project Cribrose. During the study, participants sit for a 20 second CT scan and undergo a battery of cognitive tests developed by Leucadia Therapeutics. The study will produce data for deep learning analysis of behavioral and morphological changes that may provide reliable biomarkers for pending Alzheimer’s disease. Project Cribrose is a collaboration with Neurosurgeons at Arrowhead Regional Medical Center. The study design has been reviewed and approved by Arrowhead Regional Medical Center’s Institutional review board (ARMC IRB #19-11).
Leucadia’s Patented Arethusta® Technology
Pharmaceutical companies have invested over $30 billion dollars in a series of high-profile clinical trials for Alzheimer’s disease. Even after all of this money and effort, not a single drug has been developed that can stop or even slow its relentless progression. Led by Founder and CEO Doug Ethell, PhD, Leucadia Therapeutics has looked at Alzheimer’s disease with new eyes. They have assembled an amazing team of dedicated professionals who are focused on curing Alzheimer’s disease. Their mission driven team discovered a major trigger for Alzheimer’s disease pathology and has developed a patented strategy to correct that condition.
Leucadia developed a treatment to correct this condition at the cribriform plate, a porous bony structure that becomes occluded as we age. They developed a patented implantable device called Arethusta that repairs the root cause of this pathology and restores cerebrospinal fluid flow across the cribriform plate, improving the clearance of toxic metabolites from the earliest regions of the brain to be affected by Alzheimer’s disease. This unique and compelling approach could potentially predict, halt, and cure Alzheimer’s disease. The device works in a similar way to the way that they lymphatic system clears toxins from the rest of the body. Clinical trials on Arethusta® are slated to begin in 2022.
This article was written by Margaretta Colangelo. Margaretta is Co-founder and CEO of Jthereum, an enterprise Blockchain technology company. Margaretta serves on the Advisory Boards of the AI Precision Health Institute at the University of Hawai‘i Cancer Center, NaNotics, Robots Go Mental, and on the Board of Directors of the Bring Hope Humanitarian Foundation. She serves on the advisory board of the Alliance for Longevity Initiatives and is a mentor to company founders in the Foresight Institute Biotech and Health Extension Accelerator. She is based in San Francisco. @realmargaretta